YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided group earnings guidance for the six months ended June 30, 2017. The group expected to record an increase in profit attributable to equity shareholders of approximately 40% for the six months ended 30 June 2017, as compared to the six months ended 30 June 2016. The expected increase in profit attributable to equity shareholders is primarily attributed to: (i) the continuous improvement of the academic promotion activities of the Company; (ii) the significant increase in the sales volume of Kewei and Ertongshu, the Company's key products; and (iii) the decrease in the production cost of the Company due to economies of scale and decline in price of raw materials.